Clinical Trials Arena on MSN
Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victory
Inhibrx Biosciences is vying for approval of its targeted therapy, ozekibart, in chondrosarcoma. This follows the positive ...
The US FDA and EMA in the EU have started accelerated reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, which is vying to become the first targeted therapy for this aggressive and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback